Clinical Trials Logo

Filter by:
NCT ID: NCT00519324 Completed - Clinical trials for Advanced Gastric Cancer

Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer

Start date: August 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior treatment.

NCT ID: NCT00519090 Terminated - Clinical trials for Myelogenous Leukemia

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

ENEST
Start date: October 2007
Phase: Phase 3
Study type: Interventional

In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

NCT ID: NCT00519012 Recruiting - Depression Clinical Trials

Benefits of Switching Antidepressants Following Early Nonresponse

Start date: August 2007
Phase: Phase 4
Study type: Interventional

Introduction and Purpose: Most of the guidelines for the treatment of major depression recommend the use of antidepressants for 4 to 8 weeks. On the other hand, it has been recently reported that they start to show their antidepressant efficacy within a couple of weeks (1,2), contrary to the conventional theory. In addition, a good response (i.e. a 20% reduction in the Montgomery-Åsberg Depression Rating Scale [MADRS]) at week 2 is proposed to be a predictor of subsequent remission at week 6 (3,4), while nonresponse at week 2 could predict unfavourable outcome at week 8 (5). Furthermore, early worsening is suggested to be related to a low rate of remission at weeks 8 and 12(6).

NCT ID: NCT00516750 Terminated - Bladder Cancer Clinical Trials

Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

Start date: July 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Evaluating blood or tissue samples from patients with cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and predict how well patients will respond to combination chemotherapy. PURPOSE: This phase II trial is studying gene expression profiling to see how well it works in predicting response to treatment in patients with invasive bladder cancer receiving methotrexate, vinblastine, doxorubicin, and cisplatin.

NCT ID: NCT00516672 Completed - Clinical trials for Carcinoma, Renal Cell

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Start date: September 10, 2007
Phase: Phase 1
Study type: Interventional

This is a two part phase I study in Japanese patients that will determine the safety, tolerability and pharmacokinetics of pazopanib monotherapy and of pazopanib in combination with lapatinib.

NCT ID: NCT00516451 Completed - Cancer Clinical Trials

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of this clinical study is to identify the maximum tolerated dose (MTD) of BMS-690514 once daily orally in Japanese subjects with advanced or metastatic solid tumors.

NCT ID: NCT00515450 Completed - Clinical trials for Generalized Myasthenia Gravis

Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis

Start date: July 2007
Phase: Phase 3
Study type: Interventional

This randomized controlled, multi-center study will carry out to assess the efficacy of GB-0998 compared to plasmapheresis in the treatment of the generalized Myasthenia Gravis based on the changes in Quantitative Myasthenia Gravis score (QMG score) as primary endpoint, and in addition, to assess the safety of GB-0998

NCT ID: NCT00514163 Completed - Pancreatic Cancer Clinical Trials

GEM vs GEM+TS-1 for Advanced Pancreatic Cancer

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare tumor response rate of the test arm(gemcitabine+S-1) with the control arm(gemcitabine alone) in patients with unresectable pancreatic cancer

NCT ID: NCT00512785 Completed - Overactive Bladder Clinical Trials

Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

Start date: August 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of imidafenacin.

NCT ID: NCT00511797 Completed - Dysmenorrhea Clinical Trials

SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

Start date: July 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to investigate efficacy of drospirenone for dysmenorrhea.